0
USD
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Vulvovaginal Candidiasis - Epidemiology Forecast to 2028
Published Date: April 2019
|
Report Code: DELV-Epid-439
Home | Category |Health |Health Conditions |Infectious Diseases
Vulvovaginal Candidiasis Epidemiology Forecast to 2028

Vulvovaginal Candidiasis - Epidemiology Forecast to 2028

Code: DELV-Epid-439
Report
April 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Vulvovaginal Candidiasis - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Vulvovaginal Candidiasis epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Vulvovaginal Candidiasis Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Vulvovaginal Candidiasis in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Vulvovaginal Candidiasis outlook. It also includes the explanation of changing trends of epidemiology outlining the Vulvovaginal Candidiasis scenario.

Vulvovaginal Candidiasis Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Vulvovaginal Candidiasis thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Vulvovaginal Candidiasis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Vulvovaginal Candidiasis Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Vulvovaginal Candidiasis

Key assessments
• Patient Segmentation in Vulvovaginal Candidiasis
• Vulvovaginal Candidiasis Risk & Burden
• Factors driving growth in a specific Vulvovaginal Candidiasis patient population

1. Report Introduction
2. Vulvovaginal Candidiasis Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Vulvovaginal Candidiasis in 2016
2.2. Patient Share Distribution of Vulvovaginal Candidiasis in 2028
3. Disease Background and Overview: Vulvovaginal Candidiasis
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Vulvovaginal Candidiasis in 7MM
4.3. Total Prevalent/ Incident Patient Population of Vulvovaginal Candidiasis in 7MM – By Countries
5. Epidemiology of Vulvovaginal Candidiasis by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.1.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.1.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.1.5. Diagnosed Cases of the Vulvovaginal Candidiasis
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.4.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.4.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.4.5. Diagnosed Cases of the Vulvovaginal Candidiasis
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.5.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.5.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.5.5. Diagnosed Cases of the Vulvovaginal Candidiasis
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.6.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.6.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.6.5. Diagnosed Cases of the Vulvovaginal Candidiasis
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.7.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.7.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.7.5. Diagnosed Cases of the Vulvovaginal Candidiasis
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.8.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.8.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.8.5. Diagnosed Cases of the Vulvovaginal Candidiasis
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.9.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.9.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.9.5. Diagnosed Cases of the Vulvovaginal Candidiasis
6. Unmet Needs of the Vulvovaginal Candidiasis
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Vulvovaginal Candidiasis in 7MM
Table 2: Total Prevalent/Incident Cases of the Vulvovaginal Candidiasis in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Vulvovaginal Candidiasis in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Vulvovaginal Candidiasis in United States (2016-2028)*
Table 6: Diagnosed Cases of the Vulvovaginal Candidiasis in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Vulvovaginal Candidiasis in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Vulvovaginal Candidiasis in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in France (2016-2028)
Table 12: Sub-Type Specific cases of the Vulvovaginal Candidiasis in France (2016-2028) *
Table 13: Sex- Specific Cases of the Vulvovaginal Candidiasis in France (2016-2028) *
Table 14: Diagnosed Cases of the Vulvovaginal Candidiasis in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Vulvovaginal Candidiasis in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Vulvovaginal Candidiasis in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Vulvovaginal Candidiasis in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Vulvovaginal Candidiasis in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Vulvovaginal Candidiasis in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Vulvovaginal Candidiasis in UK (2016-2028) *
Table 26: Diagnosed Cases of the Vulvovaginal Candidiasis in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Vulvovaginal Candidiasis in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Vulvovaginal Candidiasis in Japan (2016-2028)

List of Figures :

Figure 1: Total Prevalent/Incident Cases of the Vulvovaginal Candidiasis in 7MM
Figure 2: Total Prevalent/Incident Cases of the Vulvovaginal Candidiasis in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Vulvovaginal Candidiasis in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Vulvovaginal Candidiasis in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Vulvovaginal Candidiasis in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Vulvovaginal Candidiasis in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Vulvovaginal Candidiasis in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Vulvovaginal Candidiasis in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Vulvovaginal Candidiasis in France (2016-2028) *
Figure 14: Diagnosed Cases of the Vulvovaginal Candidiasis in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Vulvovaginal Candidiasis in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Vulvovaginal Candidiasis in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Vulvovaginal Candidiasis in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Vulvovaginal Candidiasis in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Vulvovaginal Candidiasis in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Vulvovaginal Candidiasis in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Vulvovaginal Candidiasis in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Vulvovaginal Candidiasis in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Vulvovaginal Candidiasis in Japan (2016-2028)

DelveInsight's "Vulvovaginal Candidiasis - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Vulvovaginal Candidiasis epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Vulvovaginal Candidiasis Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Vulvovaginal Candidiasis in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Vulvovaginal Candidiasis outlook. It also includes the explanation of changing trends of epidemiology outlining the Vulvovaginal Candidiasis scenario.

Vulvovaginal Candidiasis Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Vulvovaginal Candidiasis thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Vulvovaginal Candidiasis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Vulvovaginal Candidiasis Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Vulvovaginal Candidiasis

Key assessments
• Patient Segmentation in Vulvovaginal Candidiasis
• Vulvovaginal Candidiasis Risk & Burden
• Factors driving growth in a specific Vulvovaginal Candidiasis patient population

Read More

1. Report Introduction
2. Vulvovaginal Candidiasis Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Vulvovaginal Candidiasis in 2016
2.2. Patient Share Distribution of Vulvovaginal Candidiasis in 2028
3. Disease Background and Overview: Vulvovaginal Candidiasis
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Vulvovaginal Candidiasis in 7MM
4.3. Total Prevalent/ Incident Patient Population of Vulvovaginal Candidiasis in 7MM – By Countries
5. Epidemiology of Vulvovaginal Candidiasis by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.1.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.1.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.1.5. Diagnosed Cases of the Vulvovaginal Candidiasis
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.4.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.4.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.4.5. Diagnosed Cases of the Vulvovaginal Candidiasis
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.5.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.5.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.5.5. Diagnosed Cases of the Vulvovaginal Candidiasis
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.6.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.6.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.6.5. Diagnosed Cases of the Vulvovaginal Candidiasis
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.7.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.7.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.7.5. Diagnosed Cases of the Vulvovaginal Candidiasis
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.8.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.8.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.8.5. Diagnosed Cases of the Vulvovaginal Candidiasis
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Vulvovaginal Candidiasis
5.9.3. Sub-Type Specific cases of the Vulvovaginal Candidiasis *
5.9.4. Sex- Specific Cases of the Vulvovaginal Candidiasis *
5.9.5. Diagnosed Cases of the Vulvovaginal Candidiasis
6. Unmet Needs of the Vulvovaginal Candidiasis
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

Read More

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Vulvovaginal Candidiasis in 7MM
Table 2: Total Prevalent/Incident Cases of the Vulvovaginal Candidiasis in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Vulvovaginal Candidiasis in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Vulvovaginal Candidiasis in United States (2016-2028)*
Table 6: Diagnosed Cases of the Vulvovaginal Candidiasis in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Vulvovaginal Candidiasis in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Vulvovaginal Candidiasis in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in France (2016-2028)
Table 12: Sub-Type Specific cases of the Vulvovaginal Candidiasis in France (2016-2028) *
Table 13: Sex- Specific Cases of the Vulvovaginal Candidiasis in France (2016-2028) *
Table 14: Diagnosed Cases of the Vulvovaginal Candidiasis in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Vulvovaginal Candidiasis in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Vulvovaginal Candidiasis in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Vulvovaginal Candidiasis in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Vulvovaginal Candidiasis in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Vulvovaginal Candidiasis in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Vulvovaginal Candidiasis in UK (2016-2028) *
Table 26: Diagnosed Cases of the Vulvovaginal Candidiasis in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Vulvovaginal Candidiasis in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Vulvovaginal Candidiasis in Japan (2016-2028)

List of Figures :

Figure 1: Total Prevalent/Incident Cases of the Vulvovaginal Candidiasis in 7MM
Figure 2: Total Prevalent/Incident Cases of the Vulvovaginal Candidiasis in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Vulvovaginal Candidiasis in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Vulvovaginal Candidiasis in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Vulvovaginal Candidiasis in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Vulvovaginal Candidiasis in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Vulvovaginal Candidiasis in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Vulvovaginal Candidiasis in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Vulvovaginal Candidiasis in France (2016-2028) *
Figure 14: Diagnosed Cases of the Vulvovaginal Candidiasis in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Vulvovaginal Candidiasis in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Vulvovaginal Candidiasis in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Vulvovaginal Candidiasis in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Vulvovaginal Candidiasis in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Vulvovaginal Candidiasis in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Vulvovaginal Candidiasis in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Vulvovaginal Candidiasis in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Vulvovaginal Candidiasis in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Vulvovaginal Candidiasis in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Vulvovaginal Candidiasis in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Vulvovaginal Candidiasis in Japan (2016-2028)

Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Site License

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Enterprise License

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano String

RELATED REPORTS

Global Meningococcal Vaccine Market Research Report 2021
Global Meningococcal Vaccine Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-31I4138
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Latent tuberculosis Testing Market Size Status and Forecast 2021 2027
Global Latent tuberculosis Testing Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-33Z4080
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Avian Influenza Vaccines Market Research Report 2021
Global Avian Influenza Vaccines Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-9K4476
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Polio Vaccine Market Research Report 2021
Global Polio Vaccine Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-18B4237
Mon Feb 01 00:00:00 UTC 2021

Add to Cart

0 Items
X
No items in the cart.
$0.0